id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2006-P-0346-0017,FDA,FDA-2006-P-0346,FDA/CDER to Endo Pharmaceuticals - Partial Petition Approval and Denial,Other,Partial Petition Approval and Denial,2012-08-23T04:00:00Z,2012,8,2012-08-23T04:00:00Z,,2012-08-23T19:44:14Z,,0,0,09000064810ee52b
FDA-2006-P-0346-0016,FDA,FDA-2006-P-0346,Endo Pharmaceuticals - Amendment,Other,Amendment,2012-05-30T04:00:00Z,2012,5,2012-05-30T04:00:00Z,,2012-05-30T15:16:38Z,,0,0,0900006480fd877e
FDA-2006-P-0346-0013,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals, Inc. - Comment - Tab C - Background on OGD's Approval of Generic Copies of EMLA Cream Based on Pharmacokinetics",Supporting & Related Material,AMD-(Supporting and Related Material),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T18:38:59Z,,0,0,090000648045f28b
FDA-2006-P-0346-0012,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals, Inc. - Comment - Exhibit 1 - Letter from Dale Conner, Director of Bioequivalence, OGD (Oct. 5, 2006)",Supporting & Related Material,AMD-(Supporting and Related Material),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T18:38:58Z,,0,0,090000648045f288
FDA-2006-P-0346-0015,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals, Inc. - Comment - Tab A - Oral Versus Topical Dosage Form Performance",Supporting & Related Material,AMD-(Supporting and Related Material),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T18:39:02Z,,0,0,090000648045f28e
FDA-2006-P-0346-0011,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals, Inc. - Comment - Exhibit 16 - 98D-0388, C 12",Supporting & Related Material,AMD-(Supporting and Related Material),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T18:38:57Z,,0,0,090000648045f26f
FDA-2006-P-0346-0006,FDA,FDA-2006-P-0346,Endo Pharmaceuticals Inc - Citizen Petition,Other,Citizen Petition,2008-11-17T05:00:00Z,2008,11,2008-11-17T05:00:00Z,,2012-08-23T19:41:05Z,,0,0,090000648045f24f
FDA-2006-P-0346-0007,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals Inc - Tab A - October 5, 2006 Letter, Reference OGD #06-0100",Supporting & Related Material,CP-Citizen Petition (Supporting & Related Materials),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T17:09:30Z,,0,0,090000648045f252
FDA-2006-P-0346-0014,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals, Inc. - Comment - Tab B - Evaluation and Withdrawal of Draft Guidance for Topical Product Bioequivalence",Supporting & Related Material,AMD-(Supporting and Related Material),2008-11-17T05:00:00Z,2008,11,,,2008-11-17T18:39:00Z,,0,0,090000648045f28d
FDA-2006-P-0346-0008,FDA,FDA-2006-P-0346,"Endo Pharmaceuticals Inc., Correction Letter to FDA - Letter",Other,CR-Correction,2008-11-17T05:00:00Z,2008,11,2008-11-17T05:00:00Z,,2012-04-18T22:44:54Z,,0,0,090000648045f264
FDA-2006-P-0346-0005,FDA,FDA-2006-P-0346,FDA/CDER Interim Response to Endo Pharmaceuticals - Letter,Other,Letter(s),2007-06-25T04:00:00Z,2007,6,,,2012-04-18T23:20:36Z,,0,0,090000648045f26e
FDA-2006-P-0346-0004,FDA,FDA-2006-P-0346,Corrected Acknowledgement Letter to Endo Pharmaceuticals Inc,Other,Correction(s),2006-12-21T05:00:00Z,2006,12,,,2012-04-18T22:53:07Z,,0,0,090000648045f269
FDA-2006-P-0346-0003,FDA,FDA-2006-P-0346,See FDA-2006-P-0346-0004,Supporting & Related Material,Correction,2006-12-21T05:00:00Z,2006,12,,,2012-04-18T23:13:08Z,,0,0,090000648045f268
FDA-2006-P-0346-0002,FDA,FDA-2006-P-0346,See FDA-2006-P-0346-0001,Supporting & Related Material,Acknowledgement Letter/Receipt,2006-12-18T05:00:00Z,2006,12,,,2012-04-18T23:14:41Z,,0,0,090000648045f263
FDA-2006-P-0346-0001,FDA,FDA-2006-P-0346,Acknowledgement Letter to Endo Pharmaceuticals Inc,Other,Acknowledgement Letter/Receipt,2006-12-18T05:00:00Z,2006,12,,,2012-04-18T22:43:25Z,,0,0,090000648045f22c